Canada retaliates, places tariffs on $107 billion of US imports

Cboe UK DKK

ALK-Abelló A/S (ALKBC.XC)

155.05

0.00

(0.00%)

At close: February 20 at 3:53:26 PM GMT

No Tool

Measure

UNDO

Redo

All

All

Favorites

Text

Statistics

Technicals

Fibonacci

Markings

Lines

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Loading Chart for ALKBC.XC

U.S. FDA Approves Label Expansion for ALK's ODACTRA® (House Dust Mite Allergen Tablet) for Sublingual Use as Immunotherapy to Now Include Children with House Dust Mite Allergy

U.S. FDA Approves Label Expansion for ALK's ODACTRA® (House Dust Mite Allergen Tablet) for Sublingual Use as Immunotherapy to Now Include Children with House Dust Mite Allergy

FDA approves ODACTRA® for the treatment of house dust mite allergy in young children

FDA approves ODACTRA® for the treatment of house dust mite allergy in young children

Annual General Meeting in ALK-Abelló A/S on 13 March 2025

Annual General Meeting in ALK-Abelló A/S on 13 March 2025

Annual report 2024: ALK delivers 15% sales growth with profits up 65%

Annual report 2024: ALK delivers 15% sales growth with profits up 65%

Invitation to the presentation of ALK’s annual report 2024 on Wednesday, 19 February 2025

Invitation to the presentation of ALK’s annual report 2024 on Wednesday, 19 February 2025

ALK’s house dust mite tablet (ACARIZAX®) now recommended by NICE for use in the UK health system

ALK’s house dust mite tablet (ACARIZAX®) now recommended by NICE for use in the UK health system

3 Stocks Estimated To Be Trading At Discounts Of 26% To 44%

3 Stocks Estimated To Be Trading At Discounts Of 26% To 44%

3 Stocks That May Be Trading Below Estimated Value

3 Stocks That May Be Trading Below Estimated Value

ALK – Financial calendar for the 2025 financial year

ALK – Financial calendar for the 2025 financial year

Positive results advance peanut tablet to phase II development

Positive results advance peanut tablet to phase II development

ACARIZAX® approved in Europe for treatment of young children

ACARIZAX® approved in Europe for treatment of young children